Evidence map›Paper›PMID 30590402›Full record

ArticleCarcinogenesis2019

Systematic analyses of regulatory variants in DNase I hypersensitive sites identified two novel lung cancer susceptibility loci.

Juncheng Dai, Zhihua Li, Christopher I Amos, Rayjean J Hung, Adonina Tardon, Angeline S Andrew, Chu Chen, David C Christiani, Demetrios Albanes, Erik H F M van der Heijden and 27 more

Open access · hybridAbstract read
In one paragraph

Article in Carcinogenesis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Association Analysis of Driver Gene-Related Genetic Variants Identified Novel Lung Cancer Susceptibility Loci with 20,871 Lung Cancer Cases and 15,971 Controls.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors at 20 institutions in 12 countries.

Juncheng DaiDepartment of Epidemiology, Center for Global Health, International Joint Research Center, School of Public Health, Nanjing Medical University, Nanjing, China.
Zhihua LiDepartment of Epidemiology, Center for Global Health, International Joint Research Center, School of Public Health, Nanjing Medical University, Nanjing, China.
Christopher I AmosBiomedical Data Science, Geisel School of Medicine, Dartmouth College, Hanover, NH, USA.
Rayjean J HungLunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.
Adonina TardonFaculty of Medicine, IUOPA, University of Oviedo and CIBERESP, Oviedo, Spain.
Angeline S AndrewNorris Cotton Cancer Center, Geisel School of Medicine, Hanover, NH, USA.
Chu ChenPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
David C ChristianiDepartment of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Demetrios AlbanesDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Erik H F M van der HeijdenRadboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
Eric J DuellUnit of Nutrition and Cancer, Catalan Institute of Oncology (ICO), Barcelona, Spain.
Gad RennertClalit National Cancer Control Center, Carmel Medical Center, Haifa, Israel.
James D MckayInternational Agency for Research on Cancer (IARC), World Health Organization, Lyon, France.
Jian-Min YuanUniversity of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.
John K FieldRoy Castle Lung Cancer Research Programme, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, The William Duncan Building, Liverpool, UK.
Jonas ManjerUnit for Breast Surgery, Department of Surgery, Lund University, Malmö, Sweden.
Kjell GrankvistDepartment of Medical Biosciences, Umeå University, Umeå, Sweden.
Loic Le MarchandEpidemiology Program, University of Hawai'i Cancer Center, Honolulu, HI, USA.
M Dawn TeareSchool of Health and Related Research, University of Sheffield, Sheffield, South Yorkshire, UK.
Matthew B SchabathDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Melinda C AldrichDepartment of Thoracic Surgery, Division of Epidemiology, Vanderbilt University Medical Center, Nashville, TN, USA.
Ming-Sound TsaoPrincess Margaret Cancer Centre, Toronto, Ontario, Canada.
Philip LazarusDepartment of Pharmaceutical Sciences, College of Pharmacy, Washington State University, Spokane, WA, USA.
Stephen LamBritish Columbia Cancer Agency, Vancouver, British Columbia, Canada.
Stig E BojesenCopenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark.
Susanne ArnoldDivision of Medical Oncology Markey Cancer Center, Lexington, KY, USA.
Xifeng WuDepartment of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Aage HaugenDepartment of Chemical and Biological Work Environment, National Institute of Occupational Health (STAMI), Oslo, Norway.
Vladimir JanoutDepartment of Epidemiology and Public Health, Faculty of Health Sciences, Palacky University, Olomouc, Czech Republic.
Mikael JohanssonDepartment of Radiation Sciences, Umeå University, Umeå, Sweden.
Yonathan BrhaneLunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.
Ana Fernandez-SomoanoFaculty of Medicine, IUOPA, University of Oviedo and CIBERESP, Oviedo, Spain.
Lambertus A KiemeneyRadboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
Michael P A DaviesRoy Castle Lung Cancer Research Programme, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, The William Duncan Building, Liverpool, UK.
Shanbeh ZienolddinyDepartment of Chemical and Biological Work Environment, National Institute of Occupational Health (STAMI), Oslo, Norway.
Zhibin HuDepartment of Epidemiology, Center for Global Health, International Joint Research Center, School of Public Health, Nanjing Medical University, Nanjing, China.
Hongbing ShenDepartment of Epidemiology, Center for Global Health, International Joint Research Center, School of Public Health, Nanjing Medical University, Nanjing, China.
Nanjing Medical University · CNDartmouth College · USNational Institute of Occupational Health · NORadboud University Nijmegen · NLUmeå University · SEUniversidad de Oviedo · ESUniversity of Liverpool · GBUniversity of Toronto · CABC Cancer Agency · CACarmel Medical Center · ILCentre international de recherche sur le cancer · FRFred Hutch Cancer Center · USHarvard University · USInstitut Català d'Ornitologia · ESJiangsu Province Hospital · CNLund University · SEMarkey Cancer Center · USMoffitt Cancer Center · USNational Cancer Institute · USPalacký University Olomouc · CZ

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTOPHER J. BAKKENIST · 1988 to 2026
$158.0M
TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI John L. Cleveland · 1998 to 2026
$93.5M
Understanding Population Differences in Cancer: The MEC StudyU01CA164973 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI HAIMAN, CHRISTOPHER ALAN, LE MARCHAND, LOIC · 2015 to 2025
$37.4M
Translating Molecular and Clinical Data to Population Lung Cancer Risk AssessmentU19CA203654 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Rayjean J. Hung · 2017 to 2026
$23.7M
SPORE in Lung CancerP50CA119997 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI GABRILOVICH, DMITRY I · 2008 to 2012
$11.0M
Statistical Methods for Analysis of Massive Genetic and Genomic Data in Cancer ResearchR35CA197449 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI XIHONG LIN · 2015 to 2026
$10.9M
Infrastructure Support and Pilot Tissue Collection for the CARET BiorepositoryU01CA167462 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI NEUHOUSER, MARIAN L · 2018 to 2022
$2.9M
Unraveling Genetic Determinants of Lung Cancer Risk in African AmericansK07CA172294 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ALDRICH, MELINDA · 2013 to 2017
$801k
NCI NIH HHS K07 CA172294NCI NIH HHS P30 CA047904NCI NIH HHS P30 CA076292NCI NIH HHS P50 CA119997NCI NIH HHS R35 CA197449NCI NIH HHS U01 CA164973NCI NIH HHS U01 CA167462NCI NIH HHS U19 CA203654World Health Organization 001
6 · The paper itself

Abstract

DNase I hypersensitive sites (DHS) are abundant in regulatory elements, such as promoter, enhancer and transcription factor binding sites. Many studies have revealed that disease-associated variants were concentrated in DHS-related regions. However, limited studies are available on the roles of DHS-related variants in lung cancer. In this study, we performed a large-scale case-control study with 20 871 lung cancer cases and 15 971 controls to evaluate the associations between regulatory genetic variants in DHS and lung cancer susceptibility. The expression quantitative trait loci (eQTL) analysis and pathway-enrichment analysis were performed to identify the possible target genes and pathways. In addition, we performed motif-based analysis to explore the lung-cancer-related motifs using sequence kernel association test. Two novel variants, rs186332 in 20q13.3 (C>T, odds ratio [OR] = 1.17, 95% confidence interval [95% CI]: 1.10-1.24, P = 8.45 × 10-7) and rs4839323 in 1p13.2 (T>C, OR = 0.92, 95% CI: 0.89-0.95, P = 1.02 × 10-6) showed significant association with lung cancer risk. The eQTL analysis suggested that these two SNPs might regulate the expression of MRGBP and SLC16A1, respectively. What's more, the expression of both MRGBP and SLC16A1 was aberrantly elevated in lung tumor tissues. The motif-based analysis identified 10 motifs related to the risk of lung cancer (P < 1.71 × 10-4). Our findings suggested that variants in DHS might modify lung cancer susceptibility through regulating the expression of surrounding genes. This study provided us a deeper insight into the roles of DHS-related genetic variants for lung cancer.

Indexed as

Genetic Predisposition to DiseaseAgedCase-Control StudiesDeoxyribonuclease IFemaleHumansLung NeoplasmsMaleMiddle AgedPolymorphism, Single NucleotideQuantitative Trait LociDeoxyribonuclease I

Identifiers

PMID30590402
PMCPMC6783905
OpenAlexW2905909897

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.